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Trans-arterial radio-embolization (TARE) with yttrium-90 
represents one of the most efficacious approaches for the 
treatment of selected patients with advanced hepatocellular 
cancer (HCC) (1). Recent studies have confirmed the 
superiority of TARE when compared with other intra-
arterial treatments (2,3). A randomized phase II study 
comparing TARE and trans-arterial chemo-embolization 
(TACE) in HCC patients meeting Barcelona Clinic 
Liver Cancer stages A-B showed a longer median time-
to-progression (>26 vs. 6.8 months; P value =0.001), and 
a better tumor control in post-TARE cases (2). Another 
study similarly compared TARE and TACE patients 
homogeneously selected using a propensity score matching: 
also in this case, TARE presented higher overall complete 
response rates (84% vs. 58%; P value <0.001), and longer 
median progression-free survivals (564 vs. 271 days; 
P value =0.002) (3).
In the specific setting of advanced HCC, TARE presents 
the undoubtful benefit of being the sole strategy, apart 
sorafenib, able to treat tumor-related portal vein thrombosis 
(PVT). A propensity score match analysis comparing TARE 
and sorafenib showed similar efficacy in terms of tumor 
control and progression (4). A systematic review based 
on 722 patients further confirmed that TARE is a safe 
and effective treatment for HCC patients with PVT (5). 
However, prospective randomized studies are still lacking in 
this specific setting (6).
It is clear that the opportunity to use TARE for 
efficaciously down-stage advanced and not-transplantable 
cases, even initially presenting macrovascular invasion, 
represents an attractive opportunity for liver transplantation 
(LT) physicians (7-9). A study comparing 172 HCC cases 
initially bridged/down-staged with different approaches 
(TARE =93; TACE =79) and then undergoing LT showed 
a trend towards better recurrence-free survivals in down-
staged patients treated with TARE (7). Another study 
specifically investigating the ability of TARE vs. TACE to 
down-stage HCC cases from a Milan Criteria (MC)-OUT 
to a MC-IN status, showed that TARE was superior in 
terms of partial response rates (61% vs. 37%) and down-
staging achievement (58% vs. 31%) (8).
In a recent study by Levi Sandri et al., four cases even 
presenting initial tumor-related PVT were first down-
staged and then efficaciously transplanted (9). Interestingly 
enough, these four cases corresponded to approximately 
20% of all the cases down-staged using TARE, further 
suggesting that the systematic use of TARE should present 
a non-marginal role in improving the number of potentially 
transplantable patients. Another interesting aspect to 
underline was the very long waiting time reported from 
TARE to LT, with a mean time of approximately 16 months. 
As a matter of fact, in absence of available intention-to-treat 
analyses, it sounds acceptable that the proof of time should 
be retained necessary with the intent to select post-TARE 
good-responders. 
However, some concerns may also be addressed with 
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regard to the liberal use of TARE. Obviously, the high costs 
of the procedure should be at least balanced by a congruous 
number of patients efficaciously down-staged. A risk of 
radiological overestimation of post-TARE response exists. 
A study comparing radiological and pathological 
response after TARE showed that different radiological 
criteria like the modified response evaluation criteria in 
solid tumors were not able to reliably predict complete 
pathological necrosis (10). Another study confirmed such 
an evidence, however reporting that post-TARE imaging 
findings of response were somehow predictive of the degree 
of pathologic necrosis (11). 
This evidence further corroborates the attitude of Levi 
Sandri et al. to await for at least 6 months before LT, with 
the intent to confirm the effective validity of the radiological 
findings. In light of this, we should like to underline the 
role of biological markers like the alpha-fetoprotein (AFP) 
slope, as an important tool for selecting patients with HCC 
progression. In the series reported by Levi Sandri et al., all 
the cases showed an AFP slope reduction, thus confirming 
the efficacy of the treatment. 
Another important aspect to consider is the risk of post-
TARE toxicity. Such an aspect is important mainly for 
patients waiting for LT, due to the possible risk of drop-
out after liver decompensation. As a matter of fact, TARE 
should be considered only in case of patients at low-risk of 
being jeopardized by its use.
A systematic review based on 31 observational studies 
reported different complications (i.e., gastric ulcers, hepatic 
encephalopathy, cholecystitis, hepatic failure, pleural 
effusion, ascites, nausea) (12).
I t  i s  however  c l ear  tha t  TARE represent s  an 
extraordinary opportunity for HCC patients, mainly in case 
of PVT. Recent studies comparing TARE and sorafenib (13) 
or hypothesizing their combinative role (14) showed very 
interesting preliminary results.  
A recent study by Salem et al. further confirmed the great 
expectations for TARE: after a 15-year long experience and 
a series of 1,000 patients treated with TARE, the centre 
of Chicago has recently decided to adopt TARE as the 
first-line trans-arterial loco-regional treatment for all the 
patients with HCC (15).
In conclusion, TARE represents an excellent therapy 
for advanced HCC patients, mainly in presence of PVT. 
Only a very limited number of article exists investigating 
the opportunity to transplant patients initially presenting 
macrovascular invasion and efficaciously down-staged 
with TARE. It looks clear that intention-to-treat analyses 
are required, mainly with the intent to understand how 
many patients will be able to be down-staged to criteria 
of transplantability. A mandatory waiting-time of at least 
6 months looks to be another important strategy in this 
specific setting. Our opinion is that in the next future hard 
times may be unfortunately postulated for non-responders, 
mainly in terms of tumor progression, toxicity and liver 
decompensation. However, also great expectations may exist 
for patients efficaciously treated.  
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